Macula of retina

Adverum Biotechnologies Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022

REDWOOD CITY, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced financial results for the second quarter ended June 30, 2022.

Key Points: 
  • - Dosing first Phase 2 LUNA trial participant with ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) on track for the third quarter of 2022 and preliminary data anticipated throughout 2023
    REDWOOD CITY, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced financial results for the second quarter ended June 30, 2022.
  • In April 2022, the U.S. Food and Drug Administration (FDA) provided Adverum with Type C Meeting feedback.
  • Stock-based compensation expense included in research and development expenses was $1.8million for the second quarter of 2022.
  • Stock-based compensation expense included in general and administrative expenses was $3.1 million for the second quarter of 2022.

Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases

Retrieved on: 
Wednesday, June 8, 2022

In this role, Dr. Kaiser will advise on clinical development strategies for Ocular Therapeutixs retina programs including OTX-TKI, currently in Phase 1 development in the United States and Australia for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases.

Key Points: 
  • In this role, Dr. Kaiser will advise on clinical development strategies for Ocular Therapeutixs retina programs including OTX-TKI, currently in Phase 1 development in the United States and Australia for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases.
  • Dr. Kaiser is also expected to advise on pre-clinical development work for Oculars gene therapy delivery and complement inhibition development programs.
  • Prior to joining Ocular in 2021, Dr. Gurses Ozden served as the Chief Development Officer at Akouos, Inc.
  • Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.

Adverum Biotechnologies Announces New Data at the Macula Society’s 2022 Annual Meeting

Retrieved on: 
Thursday, June 2, 2022

REDWOOD CITY, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new data from the Phase 1 OPTIC study ADVM-022 (AAV.7m8-aflibercept) development program in wet age-related macular degeneration (wet AMD) will be presented during the Macula Society’s 2022 Annual Meeting in Berlin, Germany. The presentation will include an update on aflibercept protein expression data through three years post-treatment. In addition, a new analysis will compare the anatomical outcomes of a single intravitreal injection of ADVM-022 to standard-of-care bolus anti-vascular endothelial growth factor (VEGF) therapy in patients with wet AMD and will include an evaluation of the impact of baseline levels of neutralizing antibodies (NAbs) to AAV.7m8 on ADVM-022 efficacy, safety, and anatomical measures.

Key Points: 
  • The presentation will include an update on aflibercept protein expression data through three years post-treatment.
  • Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.
  • Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Mental Health Symptoms on the Rise Among the Visually Impaired

Retrieved on: 
Friday, July 30, 2021

New studies now indicate that mental health symptoms among those with vision loss are being diagnosed five times higher than the national average.

Key Points: 
  • New studies now indicate that mental health symptoms among those with vision loss are being diagnosed five times higher than the national average.
  • As baby boomers age and face age-related diseases such as macular degeneration, the incidence of vision loss or blindness is expected to double by 2050.
  • Geriatricians and behavioral health experts agree that among this aging population vision loss has risen to the forefront as a public health concern.
  • Hadley recently launched its new online learning platform, Hadley.edu , built on many months of research and development and based on the needs, wants and desires of visually impaired adults.

Clearside Biomedical to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Tuesday, August 10, 2021

Retrieved on: 
Tuesday, July 27, 2021

Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Key Points: 
  • Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
  • The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations .
  • Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases.
  • Clearsides proprietary SCS Microinjector targets the suprachoroidal space (SCS) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs.

Global Macular Edema Markets, Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 11, 2021

b'The "Global Macular Edema Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Macular Edema Epidemiology and Patient Flow Analysis - 2021, provides Macular Edema epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Macular Edema Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Macular Edema Epidemiology and Patient Flow Analysis - 2021, provides Macular Edema epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Macular Edema patients, history of the disease at the population level (Macular Edema prevalence, Macular Edema incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Macular Edema patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Macular Edema market sizing, assessing market potential, and developing drug forecast models\nIdentify Macular Edema patients segments through age groups, gender, and disease sub-types\nEvaluate Macular Edema market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210511005646/en/\n'

Ask for Help: Legally Blind Social Work Major Seeks to Serve

Retrieved on: 
Thursday, May 6, 2021

Diagnosed with Stargardt\'s at the age of 9 and pronounced legally blind, Abel refused to let it stop her from pursuing her dreams.\nStargardt\'s is a juvenile form of macular degeneration that causes the retina to deteriorate.

Key Points: 
  • Diagnosed with Stargardt\'s at the age of 9 and pronounced legally blind, Abel refused to let it stop her from pursuing her dreams.\nStargardt\'s is a juvenile form of macular degeneration that causes the retina to deteriorate.
  • "I can see better out of my peripheral vision, but it is still difficult to do all the normal things a person could," said Abel.
  • "People think glasses fix it, but they just make things slightly less blurry.
  • "But there is strength in asking for help, and I seek to carry that message into the social work field in the future.

Global Wet Age-Related Macular Degeneration Epidemiology and Patient Flow to 2035: Focus on United States, Germany, France, Italy, Spain, UK, Japan, & G7 Countries - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021

b'The "Global Wet Age-Related Macular Degeneration Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Wet Age-Related Macular Degeneration Epidemiology and Patient Flow Analysis - 2021, provides Wet Age-Related Macular Degeneration epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Wet Age-Related Macular Degeneration Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Wet Age-Related Macular Degeneration Epidemiology and Patient Flow Analysis - 2021, provides Wet Age-Related Macular Degeneration epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Wet Age-Related Macular Degeneration patients, history of the disease at the population level (Wet Age-Related Macular Degeneration prevalence, Wet Age-Related Macular Degeneration incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nWet Age-Related Macular Degeneration patient flow: Wet Age-Related Macular Degeneration prevalence, diagnosed, and drug-treated patients\nDemographics: Wet Age-Related Macular Degeneration patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Wet Age-Related Macular Degeneration market sizing, assessing market potential, and developing drug forecast models\nIdentify Wet Age-Related Macular Degeneration patients segments through age groups, gender, and disease sub-types\nEvaluate Wet Age-Related Macular Degeneration market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210506005576/en/\n'

Global Dry Age-Related Macular Degeneration Epidemiology and Patient Flow Report 2020-2035: Identify Patient Segments Through Age Groups, Gender, and Disease Sub-types - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 5, 2021

b'The "Global Dry Age-Related Macular Degeneration Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Dry Age-Related Macular Degeneration Epidemiology and Patient Flow Analysis - 2021, provides Dry Age-Related Macular Degeneration epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Dry Age-Related Macular Degeneration Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Dry Age-Related Macular Degeneration Epidemiology and Patient Flow Analysis - 2021, provides Dry Age-Related Macular Degeneration epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Dry Age-Related Macular Degeneration patients, history of the disease at the population level (Dry Age-Related Macular Degeneration prevalence, Dry Age-Related Macular Degeneration incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDry Age-Related Macular Degeneration patient flow: Dry Age-Related Macular Degeneration prevalence, diagnosed, and drug-treated patients\nDemographics: Dry Age-Related Macular Degeneration patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Dry Age-Related Macular Degeneration market sizing, assessing market potential, and developing drug forecast models\nIdentify Dry Age-Related Macular Degeneration patients segments through age groups, gender, and disease sub-types\nEvaluate Dry Age-Related Macular Degeneration market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210505005481/en/\n'

Ocutrx Continues to Modernize the Medical Telehealth Industry with Fifth Patent for In-home Visual Field Test Monitoring and Alerting

Retrieved on: 
Tuesday, May 4, 2021

The fifth patent covers a Macular Visual Field (MVF) test administered while the user is wearing the Oculenz\xe2\x84\xa2 AMD AR/XR headset.

Key Points: 
  • The fifth patent covers a Macular Visual Field (MVF) test administered while the user is wearing the Oculenz\xe2\x84\xa2 AMD AR/XR headset.
  • The patented technology is primarily associated with the at-home monitoring of individuals with Age-Related Macular Degeneration (AMD).
  • The visual field test is extremely user-friendly and takes approximately 5 minutes per eye.
  • To learn more about Ocutrx and its ground-breaking technology, please visit the company website at http://ocutrxtech.com/ .\n'